iVEAcare

iVEAcare is a San Francisco-based digital health and medical device company founded in 2018, specializing in neuromodulation therapies for chronic conditions. The company is in the pre-clinical or early clinical stage, leveraging a leadership team with deep expertise in active implantable devices from companies like Boston Scientific, Medtronic, and Guidant. Backed by venture capital, iVEAcare aims to translate its founders' proven experience in developing and securing regulatory approval for Class III devices into novel treatments for burdensome chronic diseases. Its initial focus appears to be on cardiac and neurological applications, building on the team's prior successes with devices for heart failure, pain, and other conditions.

Next-generation neuromodulation technology platforms, likely involving implantable or minimally invasive bioelectronic systems for targeted nerve stimulation to treat chronic diseases.

iVEAcare competes in the crowded neuromodulation space dominated by large, integrated players like Medtronic, Boston Scientific, and Abbott, which have broad portfolios and significant commercial resources. It also competes with a multitude of well-funded startups targeting specific neural pathways for chronic conditions. iVEAcare's primary competitive advantage is the unparalleled, direct experience of its team in taking analogous devices from concept to FDA approval and successful market launch.